ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Dermatology"

  • Abstract Number: 1495 • ACR Convergence 2021

    Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials

    Thomas Vazquez1, Jay Patel2, Daisy Yan3, Emily Keyes4, DeAnna Diaz5, Yubin Li6, Madison Grinnell6, Rui Feng7 and Victoria Werth3, 1FIU Wertheim College of Medicine, Virginia Beach, VA, 2Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, 3Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 5Philadelphia College of Medicine, Philadelphia, PA, 6Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, 7University of Pennsylvania Department of Biostatistics, Philadelphia, PA

    Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…
  • Abstract Number: 1759 • ACR Convergence 2021

    An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients

    Emily Keyes1, Anisha Jobanputra2, Madison Grinnell3, Rui Feng4, Thomas Vazquez5, DeAnna Diaz6 and Victoria Werth7, 1Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 2Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, 4University of Pennsylvania Department of Biostatistics, Philadelphia, PA, 5FIU Wertheim College of Medicine, Virginia Beach, VA, 6Philadelphia College of Medicine, Philadelphia, PA, 7Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
  • Abstract Number: 1774 • ACR Convergence 2021

    Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients

    Michelle Mulder1, Xuehui He2, Juul van den Reek2, Paulo Urbano2, Charlotte Kaffa2, Xinhui Wang3, Bram van Cranenbroek2, Esther van Rijssen2, Frank van den Hoogen4, Irma Joosten2, Wynand Alkema5, Elke de Jong2, Ruben Smeets2, Mark Wenink6 and Hans Koenen2, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Radboud University Medical Center, Nijmegen, Netherlands, 3University of Luxembourg, Belvaux, Luxembourg, 4Sint Maartenskliniek, Ubbergen, Netherlands, 5Hanze University of Applied Sciences, Groningen, Netherlands, 6Sint Maartenskliniek, Malden, Netherlands

    Background/Purpose: Early detection of psoriatic arthritis (PsA) in psoriasis (Pso) patients is crucial for timely treatment and prevention of structural joint damage. We aimed to…
  • Abstract Number: 1779 • ACR Convergence 2021

    A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)

    Nancy Shadick1, Kumiko Schnock2, Vivi Feather2, Jing Cui3, Gabriela Maica2, Alexa Marshall2, Wynona Francis2, Muibat Yussuff2, Lourdes Maria Perez Chada2, Michael E. Weinblatt2 and Joseph Merola4, 1Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
  • Abstract Number: 1796 • ACR Convergence 2021

    Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study

    Fabian Proft1, Susanne Lüders2, Theresa Hunter3, Gustavo Luna4, Valeria Rios Rodriguez1, Mikhail Protopopov1, Katharina Meier5, Georgios Kokolakis5, Kamran Ghoreschi5 and Denis Poddubnyy6, 1Charité University Medicine Berlin, Berlin, Germany, 2Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, 3Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, 4ICON plc, Stockholm, Sweden, 5Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, 6Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany

    Background/Purpose: In the absence of reliable serological and/or imaging biomarkers for early psoriatic arthritis (PsA) and an existing diagnostic delay there is a need for…
  • Abstract Number: 1822 • ACR Convergence 2021

    Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

    Peter C Taylor1, Andrew G Bushmakin2, Joseph C Cappelleri2, Pamela Young3, Rebecca Germino2, Joseph Merola4 and Gil Yosipovitch5, 1University of Oxford, Oxford, United Kingdom, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA, 4Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 5University of Miami Miller School, Florida, FL

    Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
  • Abstract Number: 2037 • ACR Convergence 2020

    Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts

    Anastasiya Muntyanu1, Bina Kassamali2, Ruth Ann Vleugels3 and Avery LaChance3, 1McGill University, Montreal, QC, Canada, 2Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…
  • Abstract Number: 0170 • ACR Convergence 2020

    Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis

    Marilyn Wan1, Michele Almonte2, Joel Gelfand1 and Alexis Ogdie2, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Given the complexity of available treatment recommendations, patients with psoriatic disease would benefit from a process fostering shared decision-making using a patient-centered approach. True…
  • Abstract Number: 0278 • ACR Convergence 2020

    Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study

    Mehmet Hocaoglu1, Mark Denis P. Davis2, Shirley-Ann Osei-Onomah3, Jesse Dabit2, Rachel Giblon2, Thomas O'Byrne2, Cynthia Crowson4 and Ali Duarte-Garcia2, 1University of Maryland Medical Center Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
  • Abstract Number: 0378 • ACR Convergence 2020

    Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis

    Joseph Merola1, Peter Taylor2, Andrew Bushmakin3, Joseph Cappelleri3, Pamela Young4, Rebecca Germino5 and Gil Yosipovitch6, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, New York, NY, 6University of Miami, Miami, FL

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
  • Abstract Number: 0500 • ACR Convergence 2020

    Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis

    Jessica Walsh1, Sophie Belman2, Courtney Carroll2, Michael Milliken2, Benjamin Haaland2, Kristina Callis Duffin2, Gerald Krueger2 and Bing-jian Feng2, 1University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are common and impair quality of life and function. The study objective was to identify phenotypes, genetic…
  • Abstract Number: 0849 • ACR Convergence 2020

    Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials

    Joan Merrill1, Kenneth Kalunian2, Richard Furie3, Kevin Winthrop4, Patricia Primakov5, Lilia Pineda6, Gabriel Abreu7 and Raj Tummala6, 1Oklahoma Medical Research Foundation, Oklahoma City, 2School of Health Sciences, University of California, La Jolla, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Oregon Health & Science University, Portland, OR, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: In the phase 2 MUSE and phase 3 TULIP-1 and TULIP-2 trials, treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor,…
  • Abstract Number: 1063 • ACR Convergence 2020

    Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro

    Christina Bax1, Yubin Li1, Spandana Maddukuri2, Adarsh Ravishankar3, Jay Patel3, Daisy Yan1, Josef Symon Concha1 and Victoria Werth1, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia

    Background/Purpose: Spirulina, a popular herbal supplement, stimulates the immune system, as determined by in vitro and in vivo studies. Our recent epidemiologic data suggest that Spirulina…
  • Abstract Number: 1404 • ACR Convergence 2020

    Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry

    Jay Patel1, Spandana Maddukuri2, Yubin Li3, Christina Bax4 and Victoria Werth3, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 4University of Pennsylvania, Department of Dermatology, Philadelphia

    Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
  • Abstract Number: 1405 • ACR Convergence 2020

    Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry

    Jay Patel1, Adarsh Ravishankar1, Spandana Maddukuri2, Christina Bax3 and Victoria Werth4, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: Antisynthetase syndrome (AS) is a systemic autoimmune disorder characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies, myositis, interstitial lung disease (ILD), mechanics hands, and…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology